학술논문
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Document Type
Article
Author
Al-Sawaf, Othman; Zhang, Can; Tandon, Maneesh; Sinha, Arijit; Fink, Anna-Maria; Robrecht, Sandra; Samoylova, Olga; Liberati, Anna M; Pinilla-Ibarz, Javier; Opat, Stephen; Sivcheva, Liliya; Le Dû, Katell; Fogliatto, Laura M; Niemann, Carsten U; Weinkove, Robert; Robinson, Sue; Kipps, Thomas J; Tausch, Eugen; Schary, William; Ritgen, Matthias; Wendtner, Clemens-Martin; Kreuzer, Karl-Anton; Eichhorst, Barbara; Stilgenbauer, Stephan; Hallek, Michael ; Fischer, Kirsten
Source
In The Lancet Oncology September 2020 21(9):1188-1200
Subject
Language
ISSN
1470-2045